We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report.
- Authors
Aya Fukuizumi; Akihiko Miyanaga; Masahiro Seike; Yasuhiro Kato; Shinji Nakamichi; Kumi Chubachi; Masaru Matsumoto; Rintaro Noro; Yuji Minegishi; Shinobu Kunugi; Kaoru Kubota; Akihiko Gemma
- Abstract
Background: Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (ALK) are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Case presentation: We describe a case of post-operative local recurrence of lung adenocarcinoma in an 81 year-old male. He underwent radiation and received chemotherapy with docetaxel, but neither treatment regimen was effective. Following identification of ALK rearrangements, crizotinib treatment was initiated. After treatment with crizotinib for 5 days, adverse events including acute renal failure (grade 2/CTCAE ver4.0) and congestive heart failure (grade 3) occurred. Crizotinib modified treatment was required. Half dose of crizotinib treatment could not control tumor progression. Ultimately, crizotinib was administrated at a dose of 250 mg twice daily every 3 day dosing for 13 months with maintenance of the anti-tumor effect. Conclusion: This is the first case report that skip schedule was more effective than dose reduction daily in crizotinib administration for ALK rearranged NSCLC patient with severe adverse events.
- Subjects
CRIZOTINIB; ANAPLASTIC lymphoma kinase; INCURABLE diseases; ONCOLOGY; CARCINOGENS
- Publication
BMC Research Notes, 2015, Vol 8, Issue 1, p1
- ISSN
1756-0500
- Publication type
Article
- DOI
10.1186/s13104-015-1126-8